Healthcare private equity firm
MedEquity Capital
- HeadquartersWaltham, MA S1
- Websitemedequity.com
- Last verifiedNovember 3, 2026
At a glance
| EBITDA range | $1M to $20M S2 |
|---|---|
| Revenue range | $5M+ S2 |
| Check size | $5M to $50M S2 |
| Deal types | Platform, Add-on, Minority, Growth S2 |
| Sectors | Healthcare Services, Dental |
What MedEquity Capital buys
MedEquity Capital is a private equity firm in Waltham, Massachusetts that invests only in lower middle market healthcare. It looks for businesses owned by founders, families or a small group of entrepreneurs, and says many of its prospects want a direct deal outside a formal sale process. A platform needs at least $5 million of revenue and $1 million to $20 million of EBITDA, and the firm invests $5 million to $50 million. Deals run from control to significant minority stakes and include buyouts, growth capital and full or partial recapitalizations, sometimes using preferred equity. It avoids biotech and development-stage products.
Its focus is provider services, specialty pharmacy, distribution, outsourcing, pharma services and technology-enabled services. Tuck-ins can be any size, so a small practice can still fit. The busiest route today is MAX Surgical Specialty Management, the oral surgery platform it backs with RF Investment Partners and Kian Capital. Its site also lists PharmaLogic, Belmar Pharma Solutions and Cardiovascular Associates of America as current holdings.
Recent deals
Announced in the 24 months before November 3, 2026.
| Date | Company | Type | Sector | Source |
|---|---|---|---|---|
| Jun 2026 | Oral and Maxillofacial Surgeons P.C. and Oral Associates of the Main LineTwo Philadelphia area oral surgery groups added to MAX | Add-on | Dental | Source |
| Feb 2026 | Oral & Maxillofacial Associates of MontclairSolo New Jersey oral surgery practice joined MAX through Riverside Oral Surgery | Add-on | Dental | Source |
| Jan 2026 | Central Park Oral and Maxillofacial Surgery and J. Bieber Oral & Maxillofacial SurgeryManhattan and Hudson Valley practices added to MAX | Add-on | Dental | Source |
| Oct 2025 | New York Oral & Maxillofacial Surgery and Dental Implant CenterMAX's first partnership in New York City | Add-on | Dental | Source |
| Aug 2025 | Greater Philadelphia Oral Surgery and Lebanon & Lancaster Oral Surgery GroupTwo Pennsylvania groups added to MAX | Add-on | Dental | Source |
| Apr 2025 | Rothman and Kim Oral & Maxillofacial Surgery and Oral and Maxillofacial Surgery of WestfieldPhiladelphia and New Jersey practices added to MAX, announced with a $77 million senior credit facility | Add-on | Dental | Source |
| Nov 2024 | New England Oral Surgery, Simpson Oral and Maxillofacial Surgery and Fairfield Oral SurgeryVermont, New York and Connecticut practices added to MAX | Add-on | Dental | Source |
Portfolio by sector
From the firm's portfolio page S3.
Cardiovascular Management Services
- Cardiovascular Associates of America
Oral and Maxillofacial Surgery Management Services
- MAX Surgical Specialty Management
Primary Care and Urgent Care
- Tristan Medical
Specialty Pharmacy
- Belmar Pharma Solutions
- PharmaLogic
Telepsychiatry Services
- Qler Solutions
Past investments: Interior Resources, LiceGuard LLC, Applecare, Inc., Crescent Healthcare, Inc., EnduraCare Therapy Management, Oncure Medical
Greymont’s take
How MedEquity Capital fits a seller
MedEquity suits a founder or family owner of a profitable healthcare business who would rather deal directly with experienced operators than run a wide auction. Its partners have been hands-on, serving as CEO or operating chairman at companies such as AppleCare, MAX and PharmaLogic, so owners should expect close involvement.
For oral surgeons, MAX has been a busy buyer, adding practices in Pennsylvania, New York and New Jersey through 2025 and 2026, and it promises surgeons clinical autonomy. Because the firm can invest from control to minority and may use preferred equity, the structure matters as much as the price. Owners should ask what security they would receive, whether MedEquity or a co-investor leads the deal, and how long it expects to hold, since its site gives no fund size or hold period.
Questions owners ask
Does MedEquity Capital buy oral surgery practices?
Yes, through MAX Surgical Specialty Management, which it backs with RF Investment Partners and Kian Capital. By July 2026 MAX supported more than 50 surgeons at over 40 locations in New Jersey, New York, Pennsylvania, Connecticut and Vermont.
What is the minimum size for a MedEquity Capital investment?
A platform needs at least $5 million of revenue and $1 million of EBITDA, up to $20 million of EBITDA. Tuck-in acquisitions can be any size, so a small practice can join one of its existing companies.
Will MedEquity Capital take a minority stake?
Yes. It invests $5 million to $50 million in positions from control to significant minority. Deals can be buyouts, growth capital, or full or partial recapitalizations that let an owner take some money out.
How involved is MedEquity Capital after it invests?
Very, based on its record. Brandon Ingersoll is operating chairman of PharmaLogic and Belmar Pharma Solutions, and Jeff Ward has served as CEO of MAX Surgical Specialty Management, Tristan Medical and AppleCare Immediate Care.
Sources
- S1MedEquity Capital home page Accessed November 3, 2026
- S2MedEquity Capital: About, approach and investment criteria Accessed November 3, 2026
- S3MedEquity Capital: Our Portfolio Accessed November 3, 2026
- S4MedEquity Capital: Our Team Accessed November 3, 2026
- S5MAX Surgical Specialty Management Names Dr. Jason M. Auerbach CEO (July 13, 2026) Accessed November 3, 2026
- S6MAX Secures $77 Million Senior Credit Facility (April 24, 2025) Accessed November 3, 2026
- S7MAX News & Insights Accessed November 3, 2026
Compiled by Greymont Advisors from public sources, including the firm’s own website and press releases. Greymont is not affiliated with MedEquity Capital. Figures are as reported on the dates shown and may have changed. Request a correction